Published in final edited form as:

Org Lett. 2009 November 19; 11(22): 5330–5333. doi:10.1021/ol902173g.

Synthesis of the Bicyclic Welwitindolinone Core via an Alkylation/Cyclization Cascade Reaction

John A. Brailsford, Ryan Lauchli, and Kenneth J. Shea

Department of Chemistry, University of California, Irvine, 1102 Natural Sciences 2, Irvine, California, 92697-2025

Abstract

Synthesis of an advanced welwitindolinone intermediate via an alkylation/cyclization reaction is reported. The key step involves a one pot Lewis acid mediated alkylation of a silylketene aminal with a furan alcohol followed by an intramolecular cyclization. The reaction is stereoselective and takes place at low temperature. The cycloadduct is highly functionalized and contains the welwitindolinone core structure.

Multiple-drug-resistance (MDR) is known to operate via several pathways to diminish the effectiveness of anti-cancer medicines used in chemotherapy.¹ Drug efflux via upregulated production of P-glycoprotein, a membrane transport protein for lipophilic molecules, is the most commonly observed MDR mechanism.² Agents that inhibit P-glycoprotein and/or are active against MDR cells have significant value in cancer treatment due to their potential application as single and combination therapies in the treatment of MDR tumors.³

In studies directed toward the discovery of biologically active natural products of blue-green algae (cyanobacteria), Moore isolated the welwitindolinone alkaloids (Figure 1) from *Hapalosiphon welwitschii* and *Westiella intricata*.⁴ The welwitindolinone family is divided into three subgroups: welwitindolinone A (**1**), welwitindolinones B (**2–4**), and welwitindolinones C (**5–7**). *N*-Methylwelwitindolinone C isothiocyanate (**7**), the major component of the lipophilic extract, was found to possess anti-fungal activity and reverse MDR in vinblastine resistant cell lines through inhibition of the drug-efflux ability of P-glycoprotein.⁵ Welwitindolinone C **6** was later identified as a tubulin-interacting agent demonstrating activity against drug resistant tumors.⁶ Structurally, these molecules are comprised of an oxindole ring linked to a terpenoid ring system containing three quaternary centers, chlorine substitution, and either an isonitrile or isothiocyanate moiety. In contrast to the other B and C welwitindolinones, **4** is epimeric at C-3.

kjshea@uci.edu.

Supporting Information Available: Experimental procedures, spectroscopic data (¹H, ¹³C) for new compounds, and CIF files for compounds **9** and **10**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Elegant syntheses of welwitindolinone A isonitrile (**1**) have been completed in the laboratories of Wood⁷ and Baran.⁸ However, in spite of many strategies,^{9,10} no total syntheses of the B and C welwitindolinones have been reported.

In an earlier report our laboratory disclosed a method for the synthesis of the [4.3.1] welwitindolinone core using a type 2 intramolecular Diels–Alder (IMDA) reaction.¹⁰ⁱ Although this route established proof of concept by providing short access to the welwitindolinone skeleton, we sought to develop a more expedient strategy for preparing the welwitindolinones.

The retrosynthetic strategy for the total synthesis of *N*-methylwelwitindolinone C isothiocyanate (**7**) constructs the bridged tetracyclic system using an intramolecular cycloaddition reaction (Scheme 1). Compound **8** possesses the welwitindolinone core structure, several functional handles, and could be accessed from either the bridged pentacycle **9** or **10**. The key transformation in our strategy is the formation of pentacyclo[4.3.1] oxindole **9** or **10** via cycloaddition of intermediate **11** or **12**, respectively, which in turn was envisioned to arise from alkylation of silyl ketene aminal **15** with substituted furan **13** or **14**. Compound **15** would arise from vinyl oxindole **16**, which would be derived from *N*-Boc-4-bromoindole (**17**).¹¹

The synthesis began from the known indole **17** prepared from 4-bromo-indole¹² (Scheme 2). *N*-Boc-4-bromo-indole (**17**) was oxidized to afford *N*-Boc-4-bromo-oxindole (**18**) via 2-indolyl boronic acid.¹³ 4-Bromo-oxindole (**19**),¹⁴ prepared by removal of the Boc group of oxindole **18**, was *N*-methylated to yield 4-bromo-*N*-methyl-oxindole (**20**). Vinylation of oxindole **20** with diethylfumarate via a Heck coupling¹⁵ furnished oxindole **16** as a mixture of olefin isomers. Vinyl oxindole **16** was treated with TBSOTf to form silyl ketene aminal **15** *in situ*. Compound **15** subsequently underwent alkylation upon treatment with furan alcohol **13** (R = H)¹⁶ to yield Diels–Alder precursor **11**. Experimental evidence suggests that the acid byproduct of the silylation reaction facilitates ionization of the furan alcohol to produce the reactive electrophilic species.¹⁷ At this low temperature cyclization of intermediate **12** produced oxa-bicyclo[4.3.1] adduct **9** as a single diastereomer in 62% yield from **16** in a one pot cascade reaction. Cycloadduct **9** contains two all-carbon quaternary centers, and all but two carbon atoms of the B and C welwitindolinones. The relative configuration of the stereogenic carbons of cycloadduct **9** were confirmed by X-ray crystallography. The esters, oxygen bridge and C-3 hydrogen are positioned on the same face of the molecule. Hydrogenation of cycloadduct **9** produced oxo-bridged **21** as a single diastereomer via addition exclusively to the exo face of the bicyclic system.

Based on an analogy to a related system using LiHMDS,¹⁸ we envisioned a base-induced ring opening of **21** to afford **22** via an elimination mechanism. Unfortunately, the desired product was not formed. Treatment of **21** with 1.3 equivalents of LiHMDS followed by quenching with ethanol-d₆ resulted in complete and exclusive incorporation of deuterium at C-3 to yield **23**. This deuterium labeling experiment indicated that the C-3 proton of the oxindole was removed selectively over the C-12 proton. Treatment of **21** with up to four equivalents of base did not result in the formation of **22**.

An alternative synthetic route employing silyloxyfuran **14** (R = OTIPS) for the alkylation of silylketene aminal **16** was pursued (Scheme 1). This sequence accesses ketone intermediate **8** in fewer steps and circumvents the problematic base mediated oxo-bridge opening reaction through the use of a labile silyl ketal.

Silyloxyfuran **14** was prepared by from furan **24**¹⁹ via metal–halogen exchange followed by 1,2-addition to acetone (Scheme 3). Due to the sensitivity of **14** to the acidic conditions used in the alkylation of desilyloxyfuran **13**, an alternative alkylation strategy was devised.

Silylketene amination **15** was isolated as the *Z*-isomer exclusively from a 7:1 (*Z:E*) mixture of **16**.²⁰ Lewis acids and solvents were evaluated for their ability to effect the desired alkylation reaction. ZnI₂ in acetonitrile enabled the alkylation of **15** with furan alcohol **14** to prepare furan **12** which underwent intramolecular cyclization to yield cycloadduct **10** as single diastereomer in 41% yield. The relative stereochemistry of **10** was verified by X-ray crystallography (Figure 2). This cascade reaction prepares a highly functionalized welwitindolinone core structure containing two all-carbon quaternary centers, sets two stereocenters, and assembles all but two carbon atoms of the B and C welwitindolinone skeleton from simple materials in short fashion. Desilylation of **10** with HF yielded a 25:1 mixture of the desired alcohol **8** to lactone **25**. Compound **8** was observed to isomerize to lactone **25** under basic solutions or during silica gel flash chromatography.²¹

Although the configuration of compound **8** at C-3 matches **4**, it is epimeric relative to the other welwitindolinones. Molecular modeling studies were pursued to gain insight concerning the relative stabilities about the epimerizable center at C-3 (Figure 3). Compound **26** with C-3 hydrogen beta was calculated to be 4.4 kcal/mol lower in energy than the C-3 epimer (epi-**26**) (DFT PBEPBE 6-311G*). At this same level of theory, the natural diastereomer of *N*-methylwelwitindolinone C isothiocyanate (**7**) is calculated to be 3.9 kcal/mol lower in energy than its C-3 epimer (DFT PBEPBE 6-311G*). This result suggests that an advanced synthetic intermediate can adopt the α -H configuration at C-3.

In conclusion, a highly functionalized welwitindolinone core structure **8** has been prepared in 8 steps from *N*-Boc-4-bromoindole (**17**) using an alkylation/cyclization cascade reaction. The relative stereochemistry of **9** and **10** has been confirmed by X-ray crystallography. Future work will focus on installation of the remaining quaternary center and functional group manipulations to prepare *N*-methylwelwitindolinone C isothiocyanate (**7**) and the related welwitindolinones.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by a grant from the National Institutes of Health. We also wish to thank Dr. Joseph W. Ziller (UCI) for X-ray crystallography, and Dr. John Greaves (UCI) for mass spectral data.

References

- Longley D, Johnston P. J. Pathol 2005;205:275–292. [PubMed: 15641020]
- Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Nat. Rev. Drug Discov 2006;5:219–234. [PubMed: 16518375]
- Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Science 2009;323:1718–1722. [PubMed: 19325113]
- Stratmann K, Moore RE, Bonjouklian R, Deeter JB, Patterson GML, Shaffer S, Smith CD, Smitka TA. J. Am. Chem. Soc 1994;116:9935–9942.
- Smith C, Zilfou J, Stratmann K, Patterson G, Moore R. Mol. Pharmacol 1995;47:241–247. [PubMed: 7870031]
- Zhang X, Smith C. Mol. Pharmacol 1996;49:288–294. [PubMed: 8632761]
- a Reisman SE, Ready JM, Weiss MM, Hasuoka A, Hirata M, Tamaki K, Ovaska TV, Smith CJ, Wood JL. J. Am. Chem. Soc 2008;130:2087–2100. [PubMed: 18198870] b Reisman SE, Ready JM, Hasuoka A, Smith CJ, Wood JL. J. Am. Chem. Soc 2006;128:1448–1449. [PubMed: 16448105]
- a Baran PS, Richter JM. J. Am. Chem. Soc 2005;127:15394–15396. [PubMed: 16262402] b Baran PS, Maimone TJ, Richter JM. Nature 2007;446:404–408. [PubMed: 17377577]

9. Reviews: a Avendaño C, Menéndez JC. *Curr. Org. Synth* 2004;1:65–82. b Menendez JC. *Topics in Heterocyclic Chemistry* 2007;11:63–101. c Brown LE, Konopelski JP. *Org. Prep. Proced. Int* 2008;40:411–445.
10. a MacKay JA, Bishop RL, Rawal VH. *Org. Lett* 2005;7:3421–3424. [PubMed: 16048307] b Greshock TJ, Funk RL. *Org. Lett* 2006;8:2643–2645. [PubMed: 16737334] c Baudoux J, Blake AJ, Simpkins NS. *Org. Lett* 2005;7:4087–4089. [PubMed: 16146358] d Boissel V, Simpkins NS, Bhalay G. *Tetrahedron Lett* 2009;50:3283–3286. e Boissel V, Simpkins NS, Bhalay G, Blake AJ, Lewis W. *Chem. Commun* 2009:1398–1400. f Tian X, Hutters AD, Douglas CJ, Garg NK. *Org. Lett* 2009;11:2349–2351. [PubMed: 19432408] g Trost BM, McDougall PJ. *Org. Lett* 2009;11:3782–3785. [PubMed: 19606876] h Jung ME, Slowinski F. *Tetrahedron Lett* 2001;42:6835–6838. i Konopelski JP, Deng H, Schiemann K, Keane JM, Olmstead MM. *Synlett* 1998:1105–1107. j Deng H, Konopelski JP. *Org. Lett* 2001;3:3001–3004. [PubMed: 11554828] k Wood JL, Holubec AA, Stoltz BM, Weiss MM, Dixon JA, Doan BD, Shamji MF, Chen JM, Heffron TP. *J. Am. Chem. Soc* 1999;121:6326–6327. l Lauchli R, Shea KJ. *Org. Lett* 2006;8:5287–5289. [PubMed: 17078699]
11. Madera, AM.; Weikert, R. J. *PCT Int. Appl. WO* 2004026831. 2004.
12. a Moyer MP, Shiurba JF, Rapoport H. *J. Org. Chem* 1986;51:5106–5110. b Nicolaou KC, Snyder SA, Huang X, Simonsen KB, Koumbis AE, Bigot A. *J. Am. Chem. Soc* 2004;126:10162–10173. [PubMed: 15303892]
13. Vazquez E, Payack JF. *Tetrahedron Lett* 2004;45:6549–6550.
14. Previous reported syntheses of **19**: a Kosuge T, Ishida H, Inaba A, Nukaya H. *Chem. Pharm. Bull* 1985;33:1414–1418. b Chao, H. *J. PCT Int. Appl. WO* 2005113511. p. 2005 c Xie J, Sun J, Zhang G, Houghten RA, Yu Y. *J. Comb. Chem* 2007;9:566–568. [PubMed: 17497930]
15. Cortese NA, Ziegler CB, Hrncz B, Heck RF. *J. Org. Chem* 1978;43:2952–2958.
16. Urban FJ, Jasys VJ, Raggon JW, Buzon RA, Hill PD, Egger JF, Weaver JD. *Synth. Commun* 2003;33:2029–2043.
17. For a discussion of these furan alcohols in solvolysis reactions: Noyce DS, Pavez HJ. *J. Org. Chem* 1972;37:2620–2623.
18. Brion F. *Tetrahedron Lett* 1982;23:5299–5302.
19. Kanoh N, Ishihara J, Yamamoto Y, Murai A. *Synthesis* 2000:1878–1893.
20. Ellis JM, Overman LE, Tanner HR, Wang J. *J. Org. Chem* 2008;73:9151–9154. [PubMed: 18855482]
21. Related rearrangements have been reported: a Schlessinger RH, Bergstrom CP. *Tetrahedron Lett* 1996;37:2133–2136. b Schlessinger RH, Pettus TRR, Springer JP, Hoogsteen K. *J. Org. Chem* 2002;59:3246–3247.

Figure 1.
Welwitindolinone Alkaloids

Scheme 1.
Retrosynthetic Analysis

Scheme 2.
Synthesis of Welwitindolinone Core

Scheme 3.
Alternate Route to Welwitindolinone Core

Figure 2.
ORTEP Drawing of **10**

Figure 3.
Relative Energy of C-3 epimers of **26**